Anderson-type manganese polyoxomolybdate hybrid nanocomposite for boosting drug delivery against breast cancer

Novel biocompatible nanocomposites (NCs) of Anderson-type manganese polyoxomolybdate (MnMo6) in chitosan imidazolium platform (MnMo6@CSIm NCs) were introduced for modulating cytotoxicity profile. The anticancer activity of optimized NCs was evaluated against breast cancer cell lines (MCF-7 & MDA...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug delivery science and technology 2023-09, Vol.87, p.104778, Article 104778
Main Authors: Mahvash, Shahrzad, Zavareh, Vajihe Azimian, Taymouri, Somayeh, Mirian, Mina, Ramezani-Aliakbari, Maryam, Dousti, Fatemeh, Rostami, Mahboubeh
Format: Article
Language:English
Subjects:
Anderson-type manganese polyoxomolybdate (MnMo6)
Anticancer activity
Apoptosis
Cell migration
Imidazolium modified chitosan (CSIm)
Nanocomposite (NC)
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novel biocompatible nanocomposites (NCs) of Anderson-type manganese polyoxomolybdate (MnMo6) in chitosan imidazolium platform (MnMo6@CSIm NCs) were introduced for modulating cytotoxicity profile. The anticancer activity of optimized NCs was evaluated against breast cancer cell lines (MCF-7 & MDA-MB-231) and HUVEC normal cells using the MTT assay. Cellular uptake, apoptosis ratio, and cell migration inhibition were also evaluated on the MDA-MB-231 cell line. The optimized pH-responsive NCs had better anticancer activity than free MnMo6 without cytotoxicity against normal HUVEC cells. The cellular uptake was about 100%, and the apoptosis value was higher (81%) than free MnMo6. Interestingly, the MnMo6@CSIm NCs inhibited the cell migration 1.5 times better than the free MnMo6. These results are fascinating to follow more pre-clinical studies. [Display omitted]
ISSN:1773-2247
DOI:10.1016/j.jddst.2023.104778